Pathophysiology and treatment of alpha 1-antitrypsin deficiency

Area of Science:

• Pulmonology
• Genetics
• Hepatology

Background:

• Alpha 1-antitrypsin (AAT) deficiency is the most common genetic cause of emphysema in adults and liver disease in children.
• Pulmonary disease arises from reduced AAT concentrations, while liver disease is linked to altered AAT molecular composition.
• Not all individuals with AAT deficiency develop clinical manifestations.

Purpose of the Study:

• To describe the pathophysiology of AAT deficiency.
• To review alpha 1-proteinase inhibitor therapy for emphysema management in AAT deficiency.
• To discuss diagnostic methods and therapeutic approaches for AAT deficiency.

Main Methods:

• Review of pathophysiology and clinical management of AAT deficiency.
• Analysis of alpha 1-proteinase inhibitor therapy, including plasma-derived and recombinant forms.
• Evaluation of clinical trial data on AAT augmentation therapy.

Main Results:

• Serum AAT phenotype determination is definitive for diagnosis.
• Supportive measures are used for liver disease; AAT augmentation therapy is used for pulmonary disease.
• Plasma-derived alpha 1-proteinase inhibitor has shown positive effects on serum and lung AAT levels with few adverse events.
• Recombinant AAT forms require further safety and efficacy evaluation.

Conclusions:

• AAT augmentation therapy appears to reduce emphysema progression in some patients.
• Further research is needed to address unanswered questions regarding AAT deficiency and replacement therapy.
• Management strategies differ for hepatic and pulmonary manifestations of AAT deficiency.